In a placebo-controlled oral study in CKD stages 1–3 patients[53] and in two uncontrolled (intravenous and oral) studies in dialysis patients, a decrease in hs-Crp, IL-6 and TNF-α was found during paricalcitol treatment[54,55]. This evidence concerns the gene IL6 and chronic kidney disease.